dr. shah on the rationale for the keynote-590 trial in esophageal carcinoma
Published 3 years ago • 236 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:31
dr. shah highlights immunotherapy in esophageal cancer
-
1:19
dr. kelly on the rationale for the checkmate-577 trial in esophageal/gej cancer
-
2:23
pembrolizumab plus chemotherapy for esophageal cancer: keynote-590
-
1:30
dr. shah on the role of immunotherapy in gastroesophageal cancer
-
8:45
keynote-590: pembrolizumab plus chemotherapy for advanced oesophageal cancer
-
1:08
dr. chung on the rationale of the keynote-811 trial in her2 gastric cancer
-
43:05
treatment of esophageal cancer in 2021 | zev a. wainberg, md | professor of medicine, ucla
-
18:59
controversy debate 2: selecting optimal treatments for esophagus cancer - whom to operate upon?
-
1:55
ken kato, md, phd, shares the design and outcomes of the keynote-590 trial from esmo 2020
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
59:58
management of esophageal/gej cancers: an interdisciplinary tumor board on adjuvant immunotherapy
-
3:57
cancer of the esophagus - dr. manish a. shah
-
9:04
debate: is surgery required after chemoradiotherapy for squamous cancer of the esophagus? - no
-
30:31
gastroesophageal cancer: current positioning of immunotherapy
-
13:46
2021 west oncology | gastrointestinal cancers | immuno-oncology in upper gi
-
0:30
dr. grothey on trastuzumab for gastroesophageal cancer
-
1:44
dr. mamdani on the need for novel therapies in locally advanced esophageal/gej adenocarcinoma
-
11:51
debate: what is the optimal therapy for gej cancers? - cross
-
0:56
dr. ku on immunotherapy for gastric and esophageal cancer